PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
PainReform Ltd. stock (symbol: PRFX) underwent a total of 3 stock splits.
The most recent stock split occured on Nov 21, 2024.
Date | Splite | Multiple |
---|---|---|
2024-11-21 | 1:4 | 1 |
2024-09-09 | 1:6 | 1 |
2023-07-03 | 1:10 | 1 |